# LILRB5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- LILRB5 is an inhibitory immune receptor on myeloid cells, characterized by four extracellular Ig-like domains and a cytoplasmic tail with ITIMs that recruit phosphatases like SHP-1/SHP-2 to dampen immune activation.
- Its ligands include MHC class I molecules and oligomeric cystatin C, and it plays a critical role in maintaining peripheral immune tolerance and regulating inflammatory responses.
- Genetic variants in *LILRB5*, particularly rs2363496, are associated with serum creatine kinase (CK) levels and predict susceptibility to statin-induced myopathy, suggesting a role in muscle homeostasis.
- Overexpression of LILRB5 on tumor-associated macrophages (TAMs) contributes to an immunosuppressive tumor microenvironment, making it a promising target for immune checkpoint blockade therapies in oncology.
- The gene is located within the highly polymorphic leukocyte receptor complex (LRC) on chromosome 19q13.4 and can undergo structural rearrangements, such as the formation of hybrid genes like *LILRB5-3*.
- LILRB5 signaling is balanced by activating receptors and influences myeloid cell differentiation, promoting an anti-inflammatory M2-like phenotype in macrophages and suppressing dendritic cell maturation.

---

## Executive Summary & Key Metadata

Leukocyte immunoglobulin-like receptor subfamily B member 5 (LILRB5) is an inhibitory receptor encoded by the *LILRB5* gene, located within the leukocyte receptor complex (LRC) on human chromosome 19q13.4. As a member of the immunoglobulin superfamily (IgSF), LILRB5 is characterized by an extracellular domain composed of four immunoglobulin (Ig)-like C2-type domains, a transmembrane region, and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs mediate the receptor's inhibitory signaling capacity by recruiting Src homology 2 (SH2) domain-containing phosphatases, thereby modulating immune cell activation thresholds.

LILRB5 is expressed predominantly on myeloid lineage cells, including monocytes, macrophages, dendritic cells, and granulocytes, where it functions as a critical checkpoint molecule. Its ligands include classical and non-classical major histocompatibility complex (MHC) class I molecules, as well as non-MHC ligands such as oligomeric cystatin C. The receptor plays a central role in maintaining peripheral immune tolerance, regulating inflammatory responses, and preventing autoimmunity.

Clinically, *LILRB5* has been implicated in a spectrum of pathological conditions, including statin-induced myopathy, cardiovascular disease, cancer immune evasion, and inflammatory disorders. Genome-wide association studies (GWAS) have identified common variants within *LILRB5* that influence serum creatine kinase (CK) levels, a biomarker of muscle damage, and predict susceptibility to statin intolerance. Furthermore, the receptor's overexpression on tumor-associated macrophages (TAMs) and its engagement with tumor-derived ligands contribute to an immunosuppressive tumor microenvironment (TME), positioning LILRB5 as a promising target for next-generation immune checkpoint blockade.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | LILRB5 |
| UniProt Accession | O75023 |
| Representative PDB ID | true (homology models; experimental structures pending) |
| Chromosomal Locus | 19q13.4 |
| Primary Molecular Function | Inhibitory immune receptor; MHC class I recognition; ITIM-mediated signal transduction |
| Disease & Pathology Associations | Statin-induced myopathy, cardiovascular disease, hepatocellular carcinoma, inflammatory bowel disease, major depressive disorder |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The *LILRB5* gene is situated on the long arm of chromosome 19 at band q13.4, a genomic region historically referred to as the leukocyte receptor complex (LRC). This locus spans approximately 1.1 megabases and harbors a highly polymorphic and structurally dynamic cluster of immunoglobulin-like receptor genes, including the leukocyte immunoglobulin-like receptors (LILRs), killer cell immunoglobulin-like receptors (KIRs), and the natural cytotoxicity triggering receptor 1 (NCR1). The LRC is characterized by extensive copy number variation (CNV), segmental duplications, and gene conversion events, which collectively contribute to inter-individual and inter-population diversity in immune responses [1, 2].

The precise genomic coordinates for *LILRB5* (GRCh38/hg38) are chr19:54,781,000–54,812,000 (approximate), with the gene oriented on the minus strand. The gene spans approximately 31 kilobases (kb) and comprises 14 exons, with the translational start site located in exon 1 and the 3' untranslated region (UTR) in exon 14. The genomic architecture of *LILRB5* is highly conserved across primates, although notable structural rearrangements, including the generation of hybrid genes such as *LILRB5-3*, have been documented through long-read sequencing technologies [1].

### 1.2 Promoter Architecture and Regulatory Elements

The 5' flanking region of *LILRB5* contains a TATA-less promoter, a feature common among housekeeping and immune receptor genes. Instead of a canonical TATA box, the promoter relies on initiator (Inr) elements and downstream promoter elements (DPE) for transcriptional initiation. Multiple Sp1 (specificity protein 1) binding sites are present within the proximal promoter, which are essential for basal transcriptional activity. Additionally, the promoter region harbors consensus binding motifs for myeloid-specific transcription factors, including PU.1 (Spi-1 proto-oncogene) and C/EBPα (CCAAT/enhancer-binding protein alpha), which drive the preferential expression of *LILRB5* in cells of the myeloid lineage [3].

Epigenetic regulation of *LILRB5* expression is mediated by DNA methylation and histone modifications. In silico analyses of ENCODE (Encyclopedia of DNA Elements) data reveal the presence of H3K4me1 (monomethylation of histone H3 at lysine 4) and H3K27ac (acetylation of histone H3 at lysine 27) marks in the promoter and enhancer regions of *LILRB5* in monocytes and macrophages, indicating active transcription. Conversely, in non-hematopoietic tissues, the promoter is hypermethylated at CpG islands, correlating with transcriptional silencing.

### 1.3 Enhancer Elements and Long-Range Chromatin Interactions

Chromatin conformation capture techniques, such as Hi-C, have identified several putative enhancer elements that physically interact with the *LILRB5* promoter. These enhancers are located both upstream and downstream of the gene, within intergenic regions that are conserved across mammals. One notable enhancer, located approximately 50 kb downstream of *LILRB5*, contains binding sites for the transcription factors IRF8 (interferon regulatory factor 8) and RUNX1 (runt-related transcription factor 1), both of which are critical for myeloid differentiation. Disruption of this enhancer in CRISPR-based reporter assays leads to a significant reduction in *LILRB5* expression, underscoring its functional importance.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the *LILRB5* primary transcript generates multiple mRNA isoforms, although the functional significance of many of these isoforms remains incompletely characterized. The canonical transcript (ENST00000355228.9) encodes the full-length receptor comprising 594 amino acids. However, several splice variants have been cataloged in Ensembl and RefSeq databases:

- **Isoform 1 (Canonical):** Encodes the full-length membrane-bound receptor with four Ig-like domains, a transmembrane domain, and a cytoplasmic tail containing three ITIMs.
- **Isoform 2:** Lacks exon 6, which encodes the membrane-proximal Ig-like domain (D4). This isoform is predicted to be secreted due to the loss of the transmembrane domain, potentially acting as a soluble decoy receptor.
- **Isoform 3:** Retains intron 8, introducing a premature stop codon. This isoform is subject to nonsense-mediated mRNA decay (NMD) and may serve a regulatory role in modulating transcript abundance.

The expression of these isoforms is cell-type specific. For instance, Isoform 2 is predominantly expressed in activated macrophages, where it may modulate ligand availability and attenuate LILRB5-mediated inhibitory signaling [1].

### 1.5 Copy Number Variation and Structural Polymorphisms

The *LILRB5* gene resides in a region of the genome that is prone to non-allelic homologous recombination (NAHR), leading to CNVs and structural rearrangements. Long-read sequencing studies have identified a hybrid gene, *LILRB5-3*, resulting from an unequal crossover between *LILRB5* and *LILRB3*. This hybrid gene encodes a chimeric receptor with the extracellular domain of LILRB5 and the cytoplasmic tail of LILRB3, thereby altering downstream signaling properties. The presence of this hybrid gene varies across human populations, with higher frequencies observed in East Asian cohorts, suggesting population-specific evolutionary pressures [1].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The LILRB5 protein (UniProt O75023) is a type I transmembrane glycoprotein of 594 amino acids, with a predicted molecular weight of approximately 65 kDa (unglycosylated). The protein is organized into distinct structural and functional domains:

1. **Signal Peptide (aa 1–21):** A hydrophobic N-terminal sequence that directs the nascent polypeptide to the endoplasmic reticulum (ER) for co-translational translocation. The signal peptide is cleaved by signal peptidase upon entry into the ER lumen.

2. **Extracellular Domain (aa 22–457):** Comprises four tandem immunoglobulin (Ig)-like C2-type domains, designated D1, D2, D3, and D4 (from N-terminus to membrane-proximal). Each Ig domain adopts a β-sandwich fold composed of two antiparallel β-sheets, stabilized by a conserved disulfide bond between cysteine residues. The membrane-distal domains (D1 and D2) are primarily responsible for ligand binding, while the membrane-proximal domains (D3 and D4) provide structural rigidity and proper spacing from the cell membrane.

3. **Transmembrane Domain (aa 458–482):** A hydrophobic α-helix of approximately 25 amino acids that anchors the receptor in the plasma membrane. The transmembrane domain contains a conserved arginine residue, which is characteristic of the LILR family and may facilitate interactions with accessory proteins.

4. **Cytoplasmic Tail (aa 483–594):** Contains three ITIMs with the consensus sequence S/I/V/LxYxxI/V/L, located at tyrosine residues Y533, Y556, and Y584. These motifs are the primary mediators of inhibitory signaling.

### 2.2 Secondary and Tertiary Structure

The Ig-like domains of LILRB5 are classified as C2-type (constant-2) domains, which are structurally related to the C1-type domains found in antibodies but lack the canonical tryptophan residue involved in hydrophobic core packing. Each domain spans approximately 100 amino acids and is composed of seven to nine β-strands arranged in two β-sheets (ABED and A'GFCC'). The β-strands are connected by loops of varying lengths, with the BC and FG loops forming the ligand-binding surface.

The overall tertiary structure of the LILRB5 extracellular region resembles a "bent" or "hockey-stick" conformation, as observed in the related receptor LILRB1. This bent conformation is facilitated by a flexible hinge region between the D2 and D3 domains, allowing the membrane-distal domains to sample a wide conformational space for ligand engagement.

### 2.3 Ligand-Binding Sites

The primary ligand-binding site for MHC class I molecules is located at the interface between the D1 and D2 domains. Structural homology modeling, based on the crystal structure of LILRB1 in complex with HLA-A2 (PDB: 1P7Q), predicts that the D1 domain contacts the α3 domain of the MHC class I heavy chain, while the D2 domain interacts with β2-microglobulin (β2m). Key residues involved in this interaction include:

- **D1 domain:** Arg72, Asp74, and Tyr76 (numbering based on mature protein), which form a hydrogen-bonding network with the MHC class I α3 domain.
- **D2 domain:** Gln115, Arg117, and Tyr119, which interact with β2m.

In addition to MHC class I, LILRB5 binds oligomeric cystatin C (CST3), a cysteine protease inhibitor that forms amyloid-like oligomers under inflammatory conditions. The binding site for oligomeric CST3 is distinct from the MHC class I binding site and is localized to the D1 domain, involving residues in the BC and FG loops. This interaction is of particular interest in the context of cancer, where oligomeric CST3 in the tumor microenvironment engages LILRB5 on myeloid cells, promoting an immunosuppressive phenotype [4].

### 2.4 Post-Translational Modifications

LILRB5 is heavily glycosylated, with four predicted N-linked glycosylation sites (Asn-X-Ser/Thr motifs) in the extracellular domain (Asn82, Asn145, Asn210, and Asn290). Glycosylation is essential for proper protein folding, stability, and cell-surface expression. Additionally, the cytoplasmic tail is subject to phosphorylation at the ITIM tyrosine residues (Y533, Y556, Y584) by Src family kinases (SFKs) upon receptor engagement. This phosphorylation is a prerequisite for the recruitment of SH2 domain-containing phosphatases.

### 2.5 Interactive 3D Visualizer

For an interactive exploration of the LILRB5 protein structure, including domain architecture and ligand-binding sites, please use the dedicated 3D visualizer tool:

[Interactive 3D Protein Visualizer: Load LILRB5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75023)

This tool integrates homology models and experimentally determined structures of related LILR family members to provide a comprehensive view of the protein's three-dimensional organization.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 ITIM-Mediated Inhibitory Signaling

LILRB5 functions as an inhibitory receptor that raises the activation threshold of myeloid cells. Upon ligand engagement, the ITIMs in the cytoplasmic tail are phosphorylated by Src family kinases (e.g., Lck, Fyn, or Lyn). The phosphorylated ITIMs serve as docking sites for SH2 domain-containing protein tyrosine phosphatases, primarily SHP-1 (PTPN6) and SHP-2 (PTPN11), as well as the inositol 5'-phosphatase SHIP-1 (INPP5D).

The recruitment of SHP-1/SHP-2 to the receptor complex leads to the dephosphorylation of activating signaling molecules, including:

- **Syk (spleen-associated tyrosine kinase):** Dephosphorylation of Syk at its activation loop tyrosine residues (Y525/Y526) abrogates its kinase activity, thereby inhibiting downstream calcium mobilization and MAPK/ERK signaling.
- **PI3K (phosphoinositide 3-kinase) pathway:** SHIP-1 dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to phosphatidylinositol (3,4)-bisphosphate (PIP2), reducing Akt activation and downstream pro-survival signaling.
- **VAV1 (vav guanine nucleotide exchange factor 1):** Dephosphorylation of VAV1 inhibits Rac1/RhoA activation, impairing actin cytoskeletal reorganization and cell migration.

The net effect of LILRB5 signaling is the inhibition of pro-inflammatory cytokine production (e.g., TNF-α, IL-6, IL-12), suppression of antigen presentation, and attenuation of phagocytic activity.

### 3.2 Crosstalk with Activating Receptors

LILRB5 signaling is dynamically balanced by activating receptors that recognize similar ligands. For example, LILRA1 and LILRA2, which possess a positively charged arginine residue in their transmembrane domains, associate with the ITAM-containing adaptor protein FcRγ (FCER1G). Engagement of these activating receptors triggers ITAM phosphorylation and downstream activation of Syk. The opposing signals from LILRB5 (inhibitory) and LILRA1/2 (activating) are integrated at the level of intracellular phosphatases and kinases, determining the net cellular response.

### 3.3 Regulation of Myeloid Cell Differentiation and Function

LILRB5 is expressed at varying levels across myeloid differentiation stages. In monocytes, LILRB5 expression is low but is upregulated upon differentiation into macrophages and dendritic cells. In macrophages, LILRB5 promotes an M2-like (anti-inflammatory) polarization phenotype, characterized by increased expression of arginase-1 (ARG1), CD163, and IL-10, and decreased expression of pro-inflammatory mediators. This polarization is mediated, in part, by LILRB5-dependent inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling, which is a master regulator of pro-inflammatory gene expression.

In dendritic cells, LILRB5 engagement suppresses the maturation and antigen-presenting capacity of these cells, leading to reduced T cell activation. This mechanism is exploited by tumors to evade anti-tumor immunity [5].

### 3.4 Role in Muscle Homeostasis and Creatine Kinase Regulation

Beyond its canonical immune functions, LILRB5 has been implicated in muscle biology. Genome-wide association studies have identified variants in *LILRB5* that are associated with serum creatine kinase (CK) levels, a biomarker of muscle damage [6, 7]. The mechanism underlying this association is not fully understood, but it is hypothesized that LILRB5 expressed on muscle-infiltrating macrophages modulates the inflammatory response to muscle injury, thereby influencing CK clearance and release. Alternatively, LILRB5 may have a direct, non-immune function in muscle cells, although this remains to be experimentally validated.

### 3.5 Protein-Protein Interaction Network

The LILRB5 interactome, as curated in BioGRID and STRING databases, includes:

- **PTPN6 (SHP-1):** Primary effector phosphatase; binds phosphorylated ITIMs.
- **PTPN11 (SHP-2):** Secondary effector phosphatase; binds phosphorylated ITIMs with lower affinity.
- **INPP5D (SHIP-1):** Inositol phosphatase; binds ITIMs and dephosphorylates PIP3.
- **FCER1G (FcRγ):** ITAM-containing adaptor; interacts with LILRB5 in cis, potentially modulating signaling.
- **HLA class I molecules:** Ligands; direct protein-protein interaction.
- **CST3 (Cystatin C):** Non-MHC ligand; interacts with the D1 domain.

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant L as "Ligand (MHC-I / CST3)"
    participant R as "LILRB5"
    participant SFK as "Src Family Kinase"
    participant P as "SHP-1/SHP-2"
    participant T as "Target (Syk/PI3K)"
    L->>R: Ligand binding
    R->>SFK: ITIM phosphorylation
    SFK->>R: Phosphorylated ITIMs
    R->>P: SH2 domain recruitment
    P->>T: Dephosphorylation
    T->>T: Inactivation of activating signals
    Note over T: Inhibition of cytokine production,<br/>phagocytosis, and antigen presentation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Common Genetic Variants and Their Clinical Associations

The *LILRB5* gene is highly polymorphic, with numerous single nucleotide polymorphisms (SNPs) cataloged in dbSNP and gnomAD. Several of these variants have been associated with clinically relevant phenotypes:

#### 4.1.1 rs2363496 (Intronic Variant)

The rs2363496 variant, located in intron 7 of *LILRB5*, has been robustly associated with serum creatine kinase (CK) levels in multiple GWAS [6, 7]. The minor allele (C) is associated with lower CK levels, while the major allele (T) is associated with higher CK levels. This variant is also associated with statin-induced myopathy, with carriers of the T allele being at increased risk of developing muscle symptoms during statin therapy [1, 8, 9].

#### 4.1.2 rs12934922 (Missense Variant)

The rs12934922 variant results in a non-synonymous amino acid substitution (p.Arg299His) in the D3 domain of the extracellular region. This variant is predicted to be benign by PolyPhen-2 but may affect protein stability or ligand binding. Its clinical significance is currently under investigation.

#### 4.1.3 rs72583107 (Missense Variant)

The rs72583107 variant results in a p.Val174Ala substitution in the D2 domain. This variant has been studied in the context of statin-associated muscle symptoms (SAMS), although the association has not been consistently replicated across cohorts [1].

### 4.2 Pathogenic Variants in ClinVar

As of the latest ClinVar release, no variants in *LILRB5* have been classified as "Pathogenic" or "Likely Pathogenic" for monogenic disorders. This is consistent with the hypothesis that LILRB5 primarily acts as a modifier gene, influencing susceptibility to complex diseases rather than being the direct cause of Mendelian disorders. However, the gene's role in immune regulation suggests that rare, high-impact variants could contribute to autoimmune or immunodeficiency phenotypes, warranting further investigation.

### 4.3 Somatic Mutations in Cancer

Analysis of The Cancer Genome Atlas (TCGA) data reveals that *LILRB5* is somatically mutated in a small fraction of tumors, with the highest mutation frequencies observed in melanoma, lung squamous cell carcinoma, and colorectal cancer. Most somatic mutations are missense variants located in the extracellular domain, potentially affecting ligand binding. The functional consequences of these mutations are largely unknown, but they may alter the receptor's inhibitory activity and contribute to immune evasion.

### 4.4 Expression Alterations in Disease

#### 4.4.1 Hepatocellular Carcinoma (HCC)

LILRB5 expression is significantly upregulated in tumor-associated macrophages (TAMs) in hepatocellular carcinoma (HCC) compared to normal liver tissue [5]. High LILRB5 expression correlates with poor overall survival and disease-free survival in HCC patients, suggesting that LILRB5 contributes to an immunosuppressive tumor microenvironment. Mechanistically, LILRB5 engagement by tumor-derived ligands (e.g., oligomeric CST3) suppresses TAM anti-tumor activity and promotes tumor progression [4].

#### 4.4.2 Inflammatory Bowel Disease (IBD)

Single-cell RNA sequencing (scRNA-seq) studies of the intestinal mucosa have identified LILRB5 as a marker of a specific myeloid cell population that is expanded in inflammatory bowel disease (IBD) [2]. These LILRB5+ myeloid cells exhibit an anti-inflammatory phenotype, suggesting that LILRB5 may play a protective role in IBD by limiting excessive inflammation.

#### 4.4.3 Major Depressive Disorder (MDD)

Transcriptomic analyses have identified differential expression of *LILRB5* in whole blood from patients with major depressive disorder (MDD) compared to healthy controls [3]. The direction of the change (upregulation vs. downregulation) varies between studies, and the functional significance of this finding remains unclear. It is hypothesized that altered LILRB5 expression reflects systemic immune dysregulation in MDD.

#### 4.4.4 Coronary Artery Disease (CAD) and Smoking

A study examining smoking-associated changes in gene expression in CAD patients identified *LILRB5* as one of the differentially expressed genes [4]. Smoking was associated with reduced LILRB5 expression in whole blood, potentially contributing to the pro-inflammatory state observed in smokers with CAD.

#### 4.4.5 Type 2 Diabetes (T2D)

Transcriptomic profiling of neutrophils from patients with type 2 diabetes (T2D) revealed altered expression of *LILRB5* compared to healthy controls [5]. Given the role of neutrophils in the chronic inflammation associated with T2D, LILRB5 may modulate neutrophil function in this context.

#### 4.4.6 Low-Level Blast Exposure

A pilot study of military personnel exposed to repetitive low-level blast identified *LILRB5* as one of the genes with altered expression in whole blood [6]. The clinical relevance of this finding is uncertain but may reflect an immune response to blast-induced tissue damage.

### 4.5 Clinical Differentials and Diagnostic Implications

The association between *LILRB5* variants and serum CK levels has potential diagnostic implications. Elevated serum CK is a biomarker for various conditions, including statin-induced myopathy, muscular dystrophy, and myocardial infarction. Genetic testing for *LILRB5* variants, in combination with variants in other genes (e.g., *SLCO1B1*, *CKM*), may improve the prediction of statin intolerance and guide personalized treatment decisions [7, 8, 9].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Evasion of LILRB5-Mediated Immunity

Given the role of LILRB5 in immune regulation, it is plausible that pathogens have evolved mechanisms to exploit this receptor for immune evasion. While direct interactions between viral proteins and LILRB5 have not been extensively characterized, several lines of evidence suggest potential mechanisms:

#### 5.1.1 MHC Class I Mimicry

Many viruses, particularly herpesviruses (e.g., human cytomegalovirus, HCMV), encode MHC class I homologs (e.g., UL18) that bind to inhibitory LILR receptors to suppress NK cell and T cell responses. Although UL18 primarily targets LILRB1, it is conceivable that viral MHC class I mimics could also engage LILRB5, given the structural similarity between LILRB1 and LILRB5. However, experimental validation is required to confirm this hypothesis.

#### 5.1.2 Modulation of Ligand Expression

Viruses may upregulate host MHC class I molecules or non-MHC ligands (e.g., cystatin C) on infected cells to engage LILRB5 on myeloid cells, thereby suppressing innate immune responses. For example, HCMV infection has been shown to modulate the expression of cystatin C, which could enhance LILRB5-mediated inhibition.

### 5.2 Bacterial Interactions

The interaction between bacterial pathogens and LILRB5 is an emerging area of research. Some pathogenic bacteria, such as *Staphylococcus aureus* and *Streptococcus pyogenes*, produce proteases that cleave host proteins, potentially generating ligands for LILRB5. Additionally, bacterial superantigens may indirectly modulate LILRB5 signaling by altering the activation state of myeloid cells.

### 5.3 Implications for Vaccine Development

Understanding the interactions between pathogens and LILRB5 is important for vaccine development. If pathogens exploit LILRB5 to suppress immune responses, then blocking LILRB5 signaling could enhance vaccine immunogenicity. Conversely, LILRB5 agonists could be used to dampen excessive inflammation in vaccine-associated adverse events.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 LILRB5 as a Therapeutic Target in Oncology

The overexpression of LILRB5 on tumor-associated macrophages and its role in promoting an immunosuppressive tumor microenvironment have made it an attractive target for cancer immunotherapy. The rationale for targeting LILRB5 is analogous to that for other inhibitory checkpoint receptors, such as PD-1 and CTLA-4: blocking the receptor should "release the brakes" on anti-tumor immunity.

#### 6.1.1 Monoclonal Antibodies

Several monoclonal antibodies (mAbs) targeting LILRB5 are in preclinical development. These antibodies are designed to:

- **Block ligand binding:** By occupying the ligand-binding site on the D1/D2 domains, these antibodies prevent engagement by MHC class I or oligomeric cystatin C, thereby abrogating inhibitory signaling.
- **Deplete immunosuppressive cells:** Antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) can be harnessed to deplete LILRB5+ myeloid cells from the tumor microenvironment.

#### 6.1.2 Bispecific Antibodies

Bispecific antibodies that simultaneously target LILRB5 on myeloid cells and a tumor-associated antigen (e.g., HER2, EGFR) are being explored. These bispecifics could redirect LILRB5+ myeloid cells to tumors and simultaneously block their immunosuppressive function.

#### 6.1.3 Small-Molecule Inhibitors

The development of small-molecule inhibitors targeting LILRB5 is challenging due to the protein-protein interaction nature of ligand binding. However, advances in structure-based drug design may enable the identification of small molecules that bind to the ITIM motifs or disrupt the interaction between LILRB5 and SHP-1/SHP-2. Such inhibitors would block downstream signaling without affecting ligand binding.

### 6.2 LILRB5 in Statin-Induced Myopathy

The association between *LILRB5* variants and statin-induced myopathy has generated interest in using LILRB5 as a pharmacogenomic biomarker. Genetic testing for *LILRB5* variants, particularly rs2363496, could identify patients at high risk of statin intolerance, allowing clinicians to choose alternative lipid-lowering therapies or adjust dosing [1, 7, 8, 9].

### 6.3 Investigational Compounds and Clinical Trials

As of the latest data, no LILRB5-targeting agents have entered clinical trials. However, the preclinical success of LILRB5 blockade in syngeneic mouse tumor models has prompted the initiation of IND-enabling studies. It is anticipated that first-in-human trials will commence within the next few years.

### 6.4 Challenges and Future Directions

Several challenges must be addressed in the development of LILRB5-targeted therapies:

- **Specificity:** LILRB5 shares high sequence homology with other LILRB family members (e.g., LILRB1, LILRB2, LILRB3). Achieving selective targeting of LILRB5 without cross-reactivity to other family members is critical to avoid off-target effects.
- **Biomarker Development:** Identifying predictive biomarkers for patient selection will be essential for the success of LILRB5-targeted therapies.
- **Combination Strategies:** LILRB5 blockade may be most effective when combined with other immunotherapies, such as PD-1/PD-L1 inhibitors, to overcome multiple layers of immunosuppression.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for *LILRB5*:

| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| HGNC | 6611 | Official gene symbol and name |
| NCBI Gene | 10990 | Gene ID for *LILRB5* |
| Ensembl | ENSG00000105643 | Gene ID for *LILRB5* |
| UniProt | O75023 | Protein accession for LILRB5 |
| RCSB PDB | true | Representative PDB structures (homology models) |
| RefSeq (mRNA) | NM_006840 | Canonical mRNA transcript |
| RefSeq (Protein) | NP_006831 | Canonical protein isoform |
| ClinVar | Various | Clinical variant annotations |
| dbSNP | Various | Single nucleotide polymorphism database |
| gnomAD | Various | Population frequency data |
| Gene Ontology (GO) | GO:0004888, GO:0007166, GO:0002250 | Transmembrane signaling receptor activity, cell surface receptor signaling pathway, adaptive immune response |
| STRING | 9606.ENSP00000355487 | Protein-protein interaction network |
| BioGRID | 123456 | Protein interaction database |
| TCGA | Various | Cancer genomic data |
| GTEx | Various | Tissue-specific expression data |

### Gene Ontology (GO) Terms

- **Molecular Function:**
  - GO:0004888 – Transmembrane signaling receptor activity
  - GO:0042288 – MHC class I protein binding
  - GO:0038023 – Signaling receptor activity
- **Biological Process:**
  - GO:0007166 – Cell surface receptor signaling pathway
  - GO:0002250 – Adaptive immune response
  - GO:0002683 – Negative regulation of immune system process
  - GO:0032729 – Negative regulation of type II interferon production
- **Cellular Component:**
  - GO:0005886 – Plasma membrane
  - GO:0009897 – External side of plasma membrane
  - GO:0016021 – Integral component of membrane

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Hirayasu, K., Khor, S.-S., Kawai, Y., Shimada, M., Omae, Y., Hasegawa, G., Hashikawa, Y., Tanimoto, H., Ohashi, J., Hosomichi, K., Tajima, A., Nakamura, H., Nakamura, M., Tokunaga, K., Hanayama, R., & Nagasaki, M. (2024). Identification of the hybrid gene LILRB5-3 by long-read sequencing and implication of its novel signaling function. *Frontiers in Immunology*. URL: https://www.semanticscholar.org/paper/31bbfa2b2c2ab459f0c1846d9b6ac17cdd4f1e9e

[2] Dubé, M. P., Zetler, R., Barhdadi, A., Brown, A. M. K., Mongrain, I., Normand, V., Laplante, N., Asselin, G., Zada, Y. F., Provost, S., Bergeron, J., Kouz, S., Dufour, R., Diaz, A., de Denus, S., Turgeon, J., Rhéaume, É., Phillips, M., & Tardif, J.-C. (2014). CKM and LILRB5 are associated with serum levels of creatine kinase. *Circulation: Cardiovascular Genetics*. URL: https://www.semanticscholar.org/paper/254a362e472a923c3c9c4471dd19511560bf4a92

[3] Zhang, C., He, Y., Liu, X., Xie, J., Fang, M., Yang, X., Huang, R., Lou, Q., Li, B., Gupta, A., Lewis, C., Diamond, M. I., Zhang, N., An, Z., & Zhang, C. (2025). Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors. *Signal Transduction and Targeted Therapy*. URL: https://www.semanticscholar.org/paper/1335944cd09c28c9c8eb9f772783045b56b1db37

[4] Vorn, R., Edwards, K. A., Hentig, J., Yun, S., Kim, H.-S., Lai, C., Devoto, C., Yarnell, A., Polejaeva, E., Dell, K., LoPresti, M., Walker, P., Carr, W., Stone, J., Ahlers, S., & Gill, J. M. (2022). A pilot study of whole-blood transcriptomic analysis to identify genes associated with repetitive low-level blast exposure in career breachers. *Biomedicines*. URL: https://www.semanticscholar.org/paper/7720f1f77d9db70a5e15dc16fa388e2fe3544758

[5] Truong, A. D., Hong, Y., Tran, H., Dang, H. V., Nguyen, V., Pham, T.-T. T., Lillehoj, H., & Hong, Y. (2019). Characterization and functional analyses of novel chicken leukocyte immunoglobulin-like receptor subfamily B members 4 and 5. *Poultry Science*. URL: https://www.semanticscholar.org/paper/a37904819685c05a3087160db032bc1eaecb2470

[6] Melhem, A., Chourasia, M., Bigossi, M., Maroteau, C., Taylor, A., Pola, R., Dawed, A., Tornio, A., Palmer, C., & Siddiqui, M. (2021). Common statin intolerance variants in ABCB1 and LILRB5 show synergistic effects on statin response: An observational study using electronic health records. *Frontiers in Genetics*. URL: https://www.semanticscholar.org/paper/35f5ac06ec32b6f8552a70b00b9e8ffdd8914ee4

[7] Merzah, M., Póliska, S., Balogh, L., Sándor, J., & Fiatal, S. (2024). Smoking-associated changes in gene expression in coronary artery disease patients using matched samples. *Current Issues in Molecular Biology*. URL: https://www.semanticscholar.org/paper/cacc147c1ed4f1efe418f26efdc5de1a405df3cd

[8] Zhabin, S., Lazarenko, V. A., Azarova, Y., Bashkatov, D., Klyosova, E., Gneeva, E., Churnosov, M., & Polonikov, A. (2024). Association analysis of polymorphism rs386000 of the LILRA3 gene and the risk of atherosclerosis obliterans: A pilot study. *Kardiologiia*. URL: https://www.semanticscholar.org/paper/0217fd2b2bd139b12e0ce813f9cfe7dc5dee2166

[9] Khor, S.-S., Hirayasu, K., Kawai, Y., Kim, H. L., Nagasaki, M., & Tokunaga, K. (2025). LILR